{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444364270
| IUPAC_name = ''N''-(2,2,2-Trifluoroethyl)-9-[4-[4-<nowiki>[[[</nowiki>4'-(trifluoromethyl)[1,1'-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9''H''-fluoren-9-carboxamde
| image = Lomitapide_skeletal.svg

<!--Clinical data-->
| tradename = Juxtapid (US), Lojuxta (EU)
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = X
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = Oral ([[Capsule (pharmacy)|capsules]])
| licence_US = Lomitapide
| licence_EU = Lojuxta

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 7439
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 182431-12-5
| CAS_supplemental = <br />{{CAS|202914-84-9}} ([[mesilate]])
| ATC_prefix = C10
| ATC_suffix = AX12
| ATC_supplemental = 
| PubChem = 9853053
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 82KUB0583F
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 72297
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09637
| synonyms = AEGR-773, BMS-201038
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8028764

<!--Chemical data-->
| chemical_formula =
| C=39 | H=37 | F=6 | N=3 | O=2
| molecular_weight = 693.719 g/mol
| smiles = FC(F)(F)c5ccc(cc5)-c1ccccc1C(=O)NC4CCN(CC4)CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c6ccccc26
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = MBBCVAKAJPKAKM-UHFFFAOYSA-N
}}

'''Lomitapide''' ([[International Nonproprietary Name|INN]], marketed as '''Juxtapid''' in the US and as '''Lojuxta ''' in the EU) is a drug used as a [[lipid-lowering agent]] for the treatment of [[familial hypercholesterolemia]], developed by [[Aegerion Pharmaceuticals]].<ref name="Spreitzer">{{cite journal
| author = H. Spreitzer
| date = 12 March 2007
| title = Neue Wirkstoffe – BMS-201038
| journal = Österreichische Apothekerzeitung
| issue = 6/2007
| pages = 268
| language = German
 }}</ref>
It has been tested in [[clinical trials]] as single treatment and in combinations with [[atorvastatin]], [[ezetimibe]] and [[fenofibrate]].<ref>{{cite journal|last=Samaha|first=Frederick F|author2=James McKenney |author3=LeAnne T Bloedon |author4=William J Sasiela |author5=Daniel J Rader |year=2008|title=Impact of the MTP-Inhibitor, AEGR-733, as Monotherapy and in Combination with Ezetimibe on Lipid Subfractions as Measured by NMR Spectroscopy|journal=Circulation|volume=118|pages=469–71|pmid=18663098|issue=5|doi=10.1161/CIRCULATIONAHA.108.792689}}</ref><ref>[http://www.pr-inside.com/aegerion-pharmaceuticals-inc-announces-aegr-r904473.htm Aegerion Pharmaceuticals, Inc. Announces AEGR-733 Phase II Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile]</ref>

The US Food and Drug Administration (FDA) approved lomitapide on 21 December 2012, as an [[orphan drug]] to reduce [[LDL cholesterol]], total [[cholesterol]], [[apolipoprotein B]], and non-high-density lipoprotein (non-HDL) cholesterol in patients with [[familial hypercholesterolemia|homozygous familial hypercholesterolemia]] (HoFH).<ref>[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm "FDA approves new orphan drug for rare cholesterol disorder"]</ref>

On 31 May 2013 the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion with a unanimous vote recommending a marketing authorization for lomitapide.<ref>European Medicines Agency: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002578/smops/Positive/human_smop_000519.jsp&mid=WC0b01ac058001d127 Lojuxta]</ref> On 31 July 2013 the European Commission approved lomitapide as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) [[apheresis]] in adult patients with HoFH.

==Mechanism of action==
Lomitapide inhibits the [[microsomal triglyceride transfer protein]] (MTP or MTTP) which is necessary for [[very low-density lipoprotein]] (VLDL) assembly and secretion in the liver.<ref name="Spreitzer" /><ref name="pmid17215532">{{Cite journal 
| last1 = Cuchel | first1 = M. 
| last2 = Bloedon | first2 = L. T. 
| last3 = Szapary | first3 = P. O. 
| last4 = Kolansky | first4 = D. M. 
| last5 = Wolfe | first5 = M. L. 
| last6 = Sarkis | first6 = A. 
| last7 = Millar | first7 = J. S. 
| last8 = Ikewaki | first8 = K. 
| last9 = Siegelman | first9 = E. S. 
| last10 = Gregg | first10 = R. E. 
| last11 = Rader | first11 = D. J. 
| title = Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia 
| journal = New England Journal of Medicine 
| volume = 356 
| pages = 148–156 
| year = 2007 
| doi = 10.1056/NEJMoa061189
| url = http://www.nejm.org/doi/pdf/10.1056/NEJMoa061189 | pmid=17215532 | issue=2
}}</ref>

On 24 December 2012, drug manufacturer Aegerion announced they had been approved by the FDA to as "an adjunct to a low-fat diet and other lipid-lowering treatments...in patients with homozygous familial hypercholesterolemia (HoFH)."<ref>{{cite web|title=FDA Approves Juxtapid for Homozygous Familial Hypercholesteolemia|url=http://www.dailyrx.com/juxtapid-reduces-cholesterol-patients-homozygous-familial-hypercholesterolemia|date=26 December 2012}}</ref><ref>{{cite press release
| url = http://ir.aegerion.com/releasedetail.cfm?ReleaseID=728650
| title = FDA Approves Aegerion Pharmaceuticals' Juxtapid (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH)
| publisher = Aegerion Pharmaceuticals
| date = 24 December 2012
}}</ref>

==Side effects==
In a Phase III study, lomitapide led to elevated [[aminotransferase]] levels and fat accumulation in the liver.<ref name="pmid17215532" />

==References==
{{Reflist}}

== External links ==
* [http://www.juxtapid.com Juxtapid (lomitapide) Capsules Official Web Site]
* [http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203858s000lbl.pdf Juxtapid prescribing information]

{{Lipid modifying agents}}

[[Category:Benzamides]]
[[Category:Biphenyls]]
[[Category:Fluorenes]]
[[Category:Hypolipidemic agents]]
[[Category:Organofluorides]]
[[Category:Piperidines]]
[[Category:Trifluoromethyl compounds]]